Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

US Politicians Are Buying These Two Stocks

AI-generated analysis

πŸ“ˆ US politicians including Reps. Cisneros and Khanna bought Boston Scientific shares in August 2026 without selling any positions during the same period.

πŸ“‰ The stock is down about 50% year-to-date after a cyberattack disrupted manufacturing and shipments, forcing the company to withdraw its third-quarter and full-year outlook.

🏭 By September 8, Boston Scientific reported that major distribution centers were shipping at or above normal levels and sterilization facilities were operating normally.

πŸ’° Second-quarter revenue rose 7.5% year over year with organic growth of 7%, driven by double-digit gains in core franchises like Interventional Cardiology and Neuromodulation.

πŸ“Š The stock trades at a forward non-GAAP P/E of 13.07x, which is approximately 30.64% below the healthcare-sector median of 18.85x.

⚠️ Bears warn that sales growth slowed for the WATCHMAN heart implant and that competitors are taking market share in US heart-rhythm treatment business.

πŸ’Έ The large Penumbra acquisition adds debt that will weigh on earnings in the first year according to bearish analysis.

πŸ›‘οΈ Bulls argue that hospitals waiting for products and rescheduling procedures suggests disrupted revenue is likely delayed rather than permanently lost.

πŸ“‰ Sales growth slowed sharply for specific products like WATCHMAN before the cyberattack, indicating underlying business slowdown concerns.

Bullish Signals
  • Boston Scientific reported second-quarter revenue growth of 7.5% year over year with organic growth of 7%, demonstrating continued business expansion.
  • Core franchises including Interventional Cardiology, Vascular Therapies, and Neuromodulation delivered double-digit organic growth in the second quarter.
  • Major distribution centers resumed shipping at or above normal levels by September 8, indicating operational recovery from the cyberattack.
  • Sterilization facilities are operating normally, mitigating concerns about long-term production capacity disruptions.
  • The stock trades at a forward non-GAAP P/E of 13.07x, significantly below the healthcare-sector median of 18.85x, suggesting potential undervaluation.
  • The company maintains strong margins and substantial cash generation despite recent operational challenges.
  • Politicians including Reps. Cisneros and Khanna purchased shares in August 2026 without selling any positions during the same period.
Risk Factors
  • The company is down about 50% year-to-date following a cyberattack that disrupted manufacturing, order processing, and shipments.
  • Boston Scientific was forced to withdraw its previous third-quarter and full-year earnings outlook due to the cyberattack impact.
  • Sales growth slowed sharply for the WATCHMAN heart implant before the cyberattack, indicating underlying business weakness.
  • Competitors are taking market share in the US heart-rhythm treatment business, posing a competitive risk.
  • The large Penumbra acquisition adds significant debt that will weigh on earnings in the first year.
  • Bears argue that the business was already showing signs of slowdown before the cyberattack occurred.
Full Analysis
Boston Scientific (BSX) shares have seen increased buying activity from US politicians, including Reps. Gilbert Ray Cisneros Jr. and Ro Khanna, who purchased the stock in August 2026 without selling any positions during that period. This follows a broader trend of political interest in the company alongside Accenture. The stock has declined approximately 50% year-to-date following a significant cyberattack that disrupted manufacturing, order processing, and shipments, leading to the withdrawal of previous earnings guidance. However, bulls argue that major distribution centers have resumed shipping at normal levels and sterilization facilities are operational, suggesting much of the revenue impact may be temporary delays rather than permanent losses. Despite the cyberattack, the company reported second-quarter revenue growth of 7.5% year-over-year with organic growth of 7%. Key franchises such as Interventional Cardiology, Vascular Therapies, and Neuromodulation delivered double-digit organic growth. Analysts note that BSX trades at a forward P/E of 13.07x, significantly below the healthcare sector median, while maintaining strong margins and substantial cash generation. Bearish concerns focus on slowing sales for specific products like the WATCHMAN heart implant and potential customer attrition to rivals following the cyberattack. Additionally, the large Penumbra acquisition adds debt that is expected to weigh on earnings in the first year, though bulls maintain that the market may be overreacting to the severity of the situation.